Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
PLoS One ; 17(1): e0261263, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35041671

RESUMEN

BACKGROUND: The purpose of this article is to illustrate the application of an evidence-based, structured performance measurement methodology to identify, prioritize, and (when appropriate) generate new measures of health care quality, using primary care as a case example. Primary health care is central to the health care system and health of the American public; thus, ensuring high quality is essential. Due to its complexity, ensuring high-quality primary care requires measurement frameworks that can assess the quality of the infrastructure, workforce configurations, and processes available. This paper describes the use of the Productivity Measurement and Enhancement System (ProMES) to compile a targeted set of such measures, prioritized according to their contribution and value to primary care. METHODS: We adapted ProMES to select and rank existing primary care measures according to value to the primary care clinic. Nine subject matter experts (SMEs) consisting of clinicians, hospital leaders and national policymakers participated in facilitated expert elicitation sessions to identify objectives of performance, corresponding measures, and priority rankings. RESULTS: The SMEs identified three fundamental objectives: access, patient-health care team partnerships, and technical quality. The SMEs also selected sixteen performance indicators from the 44 pre-vetted, currently existing measures from three different data sources for primary care. One indicator, Team 2-Day Post Discharge Contact Ratio, was selected as an indicator of both team partnerships and technical quality. Indicators were prioritized according to value using the contingency functions developed by the SMEs. CONCLUSION: Our article provides an actionable guide to applying ProMES, which can be adapted to the needs of various industries, including measure selection and modification from existing data sources, and proposing new measures. Future work should address both logistical considerations (e.g., data capture, common data/programming language) and lingering measurement challenges, such as operationalizating measures to be meaningful and interpretable across health care settings.


Asunto(s)
Cuidados Posteriores
2.
Placenta ; 96: 1-9, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32421527

RESUMEN

INTRODUCTION: Maternal nutrient partitioning, uteroplacental blood flow, transporter activity, and fetoplacental metabolism mediate nutrient delivery to the fetus. Inadequate availability or delivery of nutrients results in intrauterine growth restriction (IUGR), a leading cause of neonatal morbidity and mortality. Maternal nutrient restriction can result in IUGR, but only in an unforeseeable subset of individuals. METHODS: To elucidate potential mechanisms regulating fetal nutrient availability, singleton sheep pregnancies were generated by embryo transfer. Pregnant ewes received either a 50% NRC (NR; n = 24) or 100% NRC (n = 7) diet from gestational Day 35 until necropsy on Day 125. Maternal weight did not correlate with fetal weight; therefore, the six heaviest (NR Non-IUGR) and five lightest (NR IUGR) fetuses from nutrient-restricted ewes, and seven 100% NRC fetuses, were compared to investigate differences in nutrient availability. RESULTS: Insulin, multiple amino acids, and their metabolites, were reduced in fetal circulation of NR IUGR compared to NR Non-IUGR and 100% NRC pregnancies. In contrast, glucose in fetal fluids was not different between groups. There was a nearly two-fold reduction in placentome volume and fetal/maternal interface length in NR IUGR compared to NR Non-IUGR and 100% NRC pregnancies. Changes in amino acid concentrations were associated with altered expression of cationic (SLC7A2, SLC7A6, and SLC7A7) and large neutral (SLC38A2) amino acid transporters in placentomes. DISCUSSION: Results establish a novel approach to study placental adaptation to maternal undernutrition in sheep and support the hypothesis that amino acids and polyamines are critical mediators of placental and fetal growth in sheep.


Asunto(s)
Adaptación Fisiológica/fisiología , Restricción Calórica , Retardo del Crecimiento Fetal/metabolismo , Fenómenos Fisiologicos Nutricionales Maternos/fisiología , Placenta/metabolismo , Aminoácidos/sangre , Fenómenos Fisiológicos Nutricionales de los Animales/fisiología , Animales , Dieta , Femenino , Desarrollo Fetal/fisiología , Insulina/sangre , Intercambio Materno-Fetal , Circulación Placentaria/fisiología , Embarazo , Ovinos
3.
FP Essent ; 483: 30-35, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31411847

RESUMEN

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second most common cause of cancer mortality worldwide. It was estimated that approximately 50,630 mortalities due to CRC would occur in the United States in 2018. Seventy percent of CRC originates from adenomatous polyps that become dysplastic over time. Risk factors for CRC include genetic syndromes, such as familial polyposis syndromes and Lynch syndrome; inflammatory bowel disease; dietary and lifestyle factors; and family history of advanced adenomas. The U.S. Preventive Services Task Force and the U.S. Multi-Society Task Force on CRC recommend screening beginning at age 50 years for patients at average risk. Multiple screening tools may be offered based on availability and patient comorbid conditions, personal preferences, and risk factors. In the United States, colonoscopy continues to be the screening modality of choice but is not without risks and adverse effects. Currently, genetic testing has no role in the screening of patients at average risk. Research into CRC prevention is ongoing but there currently are no recommended strategies other than adequate screening.


Asunto(s)
Poliposis Adenomatosa del Colon , Neoplasias Colorrectales , Poliposis Adenomatosa del Colon/diagnóstico , Poliposis Adenomatosa del Colon/prevención & control , Colonoscopía , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/prevención & control , Detección Precoz del Cáncer , Humanos , Tamizaje Masivo , Persona de Mediana Edad , Estados Unidos
4.
Front Biosci (Elite Ed) ; 3(2): 442-52, 2011 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-21196324

RESUMEN

Recent years have witnessed an increase in the prevalence of maternal obesity during pregnancy in the United States and worldwide. Obese women have increased risks for gestational problems, such as diabetes, hypertension, and pre-eclampsia. Further, gestational obesity can adversely impact fetal growth and result in macrosomia, congenital abnormalities, and even fetal death. Measures must be taken to reduce maternal adiposity, as even a modest weight loss during pregnancy is beneficial for the health of mothers and fetus. Calorie restriction and moderate exercise are proven safe methods of stopping weight gain and/or inducing white-fat loss in these subjects. Additionally, therapeutic drugs that activate the AMP-activated protein kinase signaling pathway may be effective in ameliorating pathological conditions in obese patients. Finally, dietary supplementation with L-arginine or its effective precursor (L-citrulline) may be beneficial for managing overweight or obese gestating women by reducing white-fat accretion. Because of ethical concerns over human studies, animal models (e.g., sheep, pigs, baboons, rats, and mice) are warranted to test novel hypotheses with enormous biological significance and clinical applications.


Asunto(s)
Trastornos de la Coagulación Sanguínea/fisiopatología , Sufrimiento Fetal/fisiopatología , Hipertensión/fisiopatología , Obesidad/complicaciones , Preeclampsia/fisiopatología , Complicaciones del Embarazo/fisiopatología , Trombosis de la Vena/fisiopatología , Aminoácidos , Trastornos de la Coagulación Sanguínea/etiología , Restricción Calórica/métodos , Suplementos Dietéticos , Ejercicio Físico , Femenino , Sufrimiento Fetal/etiología , Humanos , Hipertensión/etiología , Resistencia a la Insulina/fisiología , Obesidad/tratamiento farmacológico , Obesidad/prevención & control , Preeclampsia/etiología , Embarazo , Complicaciones del Embarazo/etiología , Trombosis de la Vena/etiología
5.
Amino Acids ; 40(4): 1053-63, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20697752

RESUMEN

Proline plays important roles in protein synthesis and structure, metabolism (particularly the synthesis of arginine, polyamines, and glutamate via pyrroline-5-carboxylate), and nutrition, as well as wound healing, antioxidative reactions, and immune responses. On a per-gram basis, proline plus hydroxyproline are most abundant in collagen and milk proteins, and requirements of proline for whole-body protein synthesis are the greatest among all amino acids. Therefore, physiological needs for proline are particularly high during the life cycle. While most mammals (including humans and pigs) can synthesize proline from arginine and glutamine/glutamate, rates of endogenous synthesis are inadequate for neonates, birds, and fish. Thus, work with young pigs (a widely used animal model for studying infant nutrition) has shown that supplementing 0.0, 0.35, 0.7, 1.05, 1.4, and 2.1% proline to a proline-free chemically defined diet containing 0.48% arginine and 2% glutamate dose dependently improved daily growth rate and feed efficiency while reducing concentrations of urea in plasma. Additionally, maximal growth performance of chickens depended on at least 0.8% proline in the diet. Likewise, dietary supplementation with 0.07, 0.14, and 0.28% hydroxyproline (a metabolite of proline) to a plant protein-based diet enhanced weight gains of salmon. Based on its regulatory roles in cellular biochemistry, proline can be considered as a functional amino acid for mammalian, avian, and aquatic species. Further research is warranted to develop effective strategies of dietary supplementation with proline or hydroxyproline to benefit health, growth, and development of animals and humans.


Asunto(s)
Hidroxiprolina/metabolismo , Prolina/metabolismo , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Arginina/metabolismo , Aves , Pollos , Colágeno/química , Colágeno/metabolismo , Dieta , Suplementos Dietéticos/análisis , Peces , Ácido Glutámico/metabolismo , Glutamina/metabolismo , Humanos , Lactante , Recién Nacido , Leche/química , Leche/metabolismo , Necesidades Nutricionales , Pirroles/metabolismo , Porcinos
6.
Amino Acids ; 39(2): 349-57, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20437186

RESUMEN

Over the past 20 years, growing interest in the biochemistry, nutrition, and pharmacology of L-arginine has led to extensive studies to explore its nutritional and therapeutic roles in treating and preventing human metabolic disorders. Emerging evidence shows that dietary L-arginine supplementation reduces adiposity in genetically obese rats, diet-induced obese rats, finishing pigs, and obese human subjects with Type-2 diabetes mellitus. The mechanisms responsible for the beneficial effects of L-arginine are likely complex, but ultimately involve altering the balance of energy intake and expenditure in favor of fat loss or reduced growth of white adipose tissue. Recent studies indicate that L-arginine supplementation stimulates mitochondrial biogenesis and brown adipose tissue development possibly through the enhanced synthesis of cell-signaling molecules (e.g., nitric oxide, carbon monoxide, polyamines, cGMP, and cAMP) as well as the increased expression of genes that promote whole-body oxidation of energy substrates (e.g., glucose and fatty acids) Thus, L-arginine holds great promise as a safe and cost-effective nutrient to reduce adiposity, increase muscle mass, and improve the metabolic profile in animals and humans.


Asunto(s)
Arginina/farmacología , Arginina/uso terapéutico , Obesidad/tratamiento farmacológico , Adipocitos/citología , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/metabolismo , Tejido Adiposo Blanco/citología , Tejido Adiposo Blanco/metabolismo , Adiposidad/efectos de los fármacos , Animales , Suplementos Dietéticos , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Metabolismo de los Lípidos , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Óxido Nítrico/metabolismo , Transducción de Señal/efectos de los fármacos
7.
Amino Acids ; 37(1): 65-78, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19266154

RESUMEN

Gases, such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H(2)S), and sulfur dioxide (SO(2)) are known toxic pollutants in the air. However, they are now recognized as important signaling molecules synthesized in animals and humans from arginine, glycine (heme), and cysteine, respectively. At physiological levels, NO, CO, and SO(2) activate guanylyl cyclase to generate cGMP which elicits a variety of responses (including relaxation of vascular smooth muscle cells, hemodynamics, neurotransmission, and cell metabolism) via cGMP-dependent protein kinases. H(2)S is also a crucial regulator of both neurological function and endothelium-dependent relaxation through cGMP-independent mechanisms involving stimulation of membrane K(ATP) channels and intracellular cAMP signaling. Additionally, NO, CO, and H(2)S confer cytoprotective and immunomodulatory effects. Moreover, NH(3) is a major product of amino acid catabolism and profoundly affects the function of neurons and the vasculature through glutamine-dependent inhibition of NO synthesis. Emerging evidence shows that amino acids are not only precursors for these endogenous gases, but are also regulators of their production in a cell-specific manner. Thus, recent advances on gaseous signaling have greatly expanded our basic knowledge of amino acid biochemistry and nutrition. These exciting discoveries will aid in the design of new nutritional and pharmacological means to prevent and treat major health problems related to developmental biology and nutrient metabolism, including intrauterine growth restriction, preterm birth, aging, neurological disorders, cancer, obesity, diabetes, and cardiovascular disease.


Asunto(s)
Aminoácidos/metabolismo , Monóxido de Carbono/metabolismo , Sulfuro de Hidrógeno/metabolismo , Óxido Nítrico/biosíntesis , Dióxido de Azufre/metabolismo , Animales , Enfermedades Cardiovasculares/metabolismo , Metabolismo Energético/fisiología , Humanos , Enfermedades del Sistema Inmune/metabolismo , Enfermedades del Sistema Nervioso/metabolismo , Óxido Nítrico/metabolismo , Transducción de Señal/fisiología
8.
J Public Health Manag Pract ; 13(1): 7-15, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17149094

RESUMEN

This article presents the outcomes of a full-scale training exercise utilizing a drive-thru clinic model for dispensing of Strategic National Stockpile medication. The Hawaii Department of Health developed a clinic design for vehicles based on previous exercises and research on sample throughput rates. The streamlined model selected includes a triage area near the entrance and consecutive stations for the public to register, have an evaluation for drug contradictions, and receive the medication. During the 2-hour exercise held in April 2005, a total of 622 patients were processed in their vehicles for an overall rate of 5.2 persons per minute. Although patient services were reduced in comparison to current walk-in clinic models, the public was able to receive prophylactic medication in a timely manner with a high rate of accuracy and minimal human-to-human contact. These results demonstrate that local health departments, particularly in rural areas, can provide essential medications, vaccinations, or rations through a drive-thru clinic, thus limiting morbidity and mortality during a public health emergency.


Asunto(s)
Bioterrorismo , Servicios Comunitarios de Farmacia/organización & administración , Eficiencia Organizacional , Servicios Médicos de Urgencia , Preparaciones Farmacéuticas/provisión & distribución , Hawaii , Humanos , Evaluación de Programas y Proyectos de Salud , Salud Pública
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...